Skip Navigation LinksHome > August 24, 2014 - Volume 28 - Issue 13 > Simplification to rilpivirine/emtricitabine/tenofovir disopr...
AIDS:
doi: 10.1097/01.aids.0000453287.34039.9a
Errata

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants: Erratum

Free Access

The authors bring the following errors in their paper [1] to the attention of readers.

In the third sentence of the first paragraph of the Results on page 337, the percentage of participants who switched to RPV/FTC/TDF should be 96% instead of 94%, and who completed 24 weeks of RPV/FTC/TDF treatment should be 90% instead of 89%.

In Figure 1 on page 338, of the 159 that were randomized to stay on PI+RTV+2NRTIs and received at least one dose, for those that discontinued study before switching to RPV/FTC/TDF for ‘Withdrew consent’ it should be 3 instead of 4, and 1 for an additional reason of ‘Protocol violation’. Of the 152 that switched to RPV/FTC/TDF at week 24, for those that discontinued after switching due to ‘Withdrew consent’ should be 2 instead of 1 and for ‘Protocol violation’ should be 1 instead of 2. The corrected Figure 1 is below.  

Image Tools

On page 339, Table 1 the entry for CD4+ cell count (cells/μL) should say ‘Mean (SD)’ and not ‘Median (SD)’.

On page 341, Figure 2 the value for HDL for RPV/FTC/TDF (immediate, D1-W24) should be -4 mg/dl instead of -6 mg/dl and for RPV/FTC/TDF (delayed, W24-W48) should be -2 mg/dl instead of -4 mg/dl. The corrected upper panel of the figure is below.  

Image Tools

Back to Top | Article Outline

Reference

1. Palella FJ, Fisher M, Tebas P, Gazzard B, Ruane P, Van Lunzen J, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014; 28:335–344.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login